Impaired immunoregulatory network of the CD4 T lymphocytes in refractory asthma.


Journal

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
ISSN: 1365-2222
Titre abrégé: Clin Exp Allergy
Pays: England
ID NLM: 8906443

Informations de publication

Date de publication:
05 2019
Historique:
received: 16 07 2018
revised: 29 12 2018
accepted: 17 01 2019
pubmed: 29 1 2019
medline: 1 7 2020
entrez: 29 1 2019
Statut: ppublish

Résumé

The immunopathogenesis of severe asthma has been associated with an inefficient regulatory response. There are a few studies about the CD4 T cells profile among individuals with severe asthma refractory to treatment. To evaluate the CD4 T lymphocyte profile from individuals with severe asthma according to their response to treatment, relating to their atopy status and age of asthma onset. We evaluated nineteen individuals with severe asthma refractory to treatment (SAR), 21 with well-controlled or partly controlled severe asthma (CSA) and 23 with mild-to-moderate asthma (MMA). Lymphocytes were obtained from PBMC, and the frequency of expression of different molecules in this population was assessed using the flow cytometry. We observed the frequency of CD4 Our data suggest that refractoriness to treatment in asthma is associated with a lower expression of distinct regulatory molecules by CD4 T cells between those who are atopic and have EOA and those who are non-atopic and have LOA. Thus, these results may contribute to the identification of new regulatory strategies to treat asthma according to their phenotypes.

Sections du résumé

BACKGROUND
The immunopathogenesis of severe asthma has been associated with an inefficient regulatory response. There are a few studies about the CD4 T cells profile among individuals with severe asthma refractory to treatment.
OBJECTIVE
To evaluate the CD4 T lymphocyte profile from individuals with severe asthma according to their response to treatment, relating to their atopy status and age of asthma onset.
METHODS
We evaluated nineteen individuals with severe asthma refractory to treatment (SAR), 21 with well-controlled or partly controlled severe asthma (CSA) and 23 with mild-to-moderate asthma (MMA). Lymphocytes were obtained from PBMC, and the frequency of expression of different molecules in this population was assessed using the flow cytometry.
RESULTS
We observed the frequency of CD4
CONCLUSION AND CLINICAL RELEVANCE
Our data suggest that refractoriness to treatment in asthma is associated with a lower expression of distinct regulatory molecules by CD4 T cells between those who are atopic and have EOA and those who are non-atopic and have LOA. Thus, these results may contribute to the identification of new regulatory strategies to treat asthma according to their phenotypes.

Identifiants

pubmed: 30689261
doi: 10.1111/cea.13351
doi:

Substances chimiques

Biomarkers 0
CTLA-4 Antigen 0
CTLA4 protein, human 0
Cytokines 0
Vitamin D 1406-16-2
Immunoglobulin E 37341-29-0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

644-654

Informations de copyright

© 2019 John Wiley & Sons Ltd.

Auteurs

Jamille S Fernandes (JS)

Centro de Ciências Biológicas e da Saúde, Universidade Federal do Oeste da Bahia, Barreiras, Bahia, Brazil.
Serviço de Imunologia, Hospital Universitário Professor Edgard Santos, Universidade Federal da Bahia (UFBA), Salvador, Bahia, Brazil.
ProAR - Núcleo de Excelência em Asma, UFBA, Salvador, Bahia, Brazil.

Maria Ilma Araujo (MI)

Serviço de Imunologia, Hospital Universitário Professor Edgard Santos, Universidade Federal da Bahia (UFBA), Salvador, Bahia, Brazil.

Tarcísio V V S de Almeida (TVVS)

Serviço de Imunologia, Hospital Universitário Professor Edgard Santos, Universidade Federal da Bahia (UFBA), Salvador, Bahia, Brazil.
Escola Bahiana de Medicina e Saúde Pública, Salvador, Bahia, Brazil.

Lorena S Andrade (LS)

Serviço de Imunologia, Hospital Universitário Professor Edgard Santos, Universidade Federal da Bahia (UFBA), Salvador, Bahia, Brazil.

Diego M Lopes (DM)

Serviço de Imunologia, Hospital Universitário Professor Edgard Santos, Universidade Federal da Bahia (UFBA), Salvador, Bahia, Brazil.

Luane M de Mello (LM)

ProAR - Núcleo de Excelência em Asma, UFBA, Salvador, Bahia, Brazil.
Departamento de Medicina Social, Faculdade de Medicina de Ribeirão Preto, USP, Ribeirão Preto, São Paulo, Brazil.

Edgar M Carvalho (EM)

Serviço de Imunologia, Hospital Universitário Professor Edgard Santos, Universidade Federal da Bahia (UFBA), Salvador, Bahia, Brazil.
Laboratório de Pesquisas Clínicas, Instituto Gonçalo Moniz, FIOCRUZ, Salvador, Bahia, Brazil.
Instituto Nacional de Ciência e Tecnologia em Doenças Tropicais (INCT -DT/CNPq), Distrito Federal, Brasília, Brazil.

Álvaro A Cruz (ÁA)

ProAR - Núcleo de Excelência em Asma, UFBA, Salvador, Bahia, Brazil.

Luciana S Cardoso (LS)

Serviço de Imunologia, Hospital Universitário Professor Edgard Santos, Universidade Federal da Bahia (UFBA), Salvador, Bahia, Brazil.
Instituto Nacional de Ciência e Tecnologia em Doenças Tropicais (INCT -DT/CNPq), Distrito Federal, Brasília, Brazil.
Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, UFBA, Salvador, Bahia, Brazil.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH